← The Wire
RZLTNasdaq
Rezolute, Inc.
Pharmaceutical Preparations · NV · CIK 1509261
Rezolute, Inc. develops treatments for hypoglycemia caused by hyperinsulinism
$385M
Market cap
$5.10
Last close
+1.2%
1D
-1.0%
5D
1.8M
Volume
Price · last 39 sessions+54.5%
May 4L $3.09 · H $5.15Jun 29
308
Total filings
Jun 2, 2026
Last filing
06/30
Fiscal year end
8-KReg FD DisclosureJun 2, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 20268-KReg FD DisclosureMay 4, 20268-KReg FD DisclosureMar 24, 202610-Q10-QFeb 12, 20268-KResults of OperationsFeb 12, 20268-KReg FD DisclosureJan 7, 20268-KShareholder VoteNov 21, 20258-KReg FD DisclosureNov 12, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KExecutive Change · Material AgreementOct 21, 2025DEF 14ADEF 14AOct 7, 202510-K10-KSep 17, 20258-KResults of OperationsSep 17, 20258-KReg FD DisclosureSep 2, 20258-KExecutive Change · Material AgreementAug 20, 20258-KReg FD DisclosureJul 18, 20258-K/AExecutive ChangeJun 13, 20258-KEquity Issuance · Company UpdateJun 13, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 20258-KReg FD DisclosureApr 28, 20258-KMaterial Agreement · Equity IssuanceApr 23, 2025424B5424B5Apr 23, 2025424B5424B5Apr 23, 20258-KReg FD DisclosureApr 23, 20258-KExecutive ChangeMar 28, 202510-Q10-QFeb 12, 20258-KResults of OperationsFeb 12, 20258-KReg FD DisclosureFeb 4, 20258-KReg FD DisclosureJan 14, 20258-KReg FD DisclosureJan 7, 20258-KBylaw Amendment · Shareholder VoteDec 10, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024DEFA14ADEFA14AOct 21, 2024DEF 14ADEF 14AOct 21, 202410-K10-KSep 19, 20248-KResults of OperationsSep 19, 20248-KReg FD DisclosureSep 9, 20248-KReg FD DisclosureAug 5, 20248-KReg FD DisclosureJun 28, 20248-KMaterial Agreement · Equity IssuanceJun 27, 20248-KMaterial Agreement · Reg FD DisclosureJun 14, 2024424B5424B5Jun 14, 2024424B5424B5Jun 13, 20248-KReg FD DisclosureMay 24, 20248-KShareholder VoteMay 17, 202410-Q10-QMay 15, 20248-KResults of OperationsMay 15, 20248-KReg FD DisclosureApr 25, 2024DEF 14ADEF 14AApr 15, 20248-KAuditor Change · Material AgreementMar 14, 20248-KReg FD DisclosureMar 11, 2024SC 13GSC 13GMar 11, 20248-KCompany UpdateFeb 22, 202410-Q10-QFeb 13, 20248-KResults of OperationsFeb 13, 20248-KExecutive Change · Equity IssuanceJan 29, 20248-KReg FD DisclosureDec 14, 20238-KDelisting NoticeNov 22, 202310-Q10-QNov 13, 20238-KResults of OperationsNov 13, 20238-KReg FD DisclosureOct 18, 20238-KReg FD DisclosureOct 13, 2023SC 13GSCHEDULE 13GOct 13, 202310-K10-KSep 14, 20238-KResults of OperationsSep 14, 20238-KReg FD Disclosure · Company UpdateJun 27, 20238-KReg FD DisclosureJun 20, 20238-KCode of EthicsJun 2, 20238-KShareholder VoteMay 26, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 12, 2023DEF 14ADEF 14AApr 12, 2023SC 13GSC 13GFeb 14, 202310-Q10-QFeb 10, 2023
Insider Activity
In the 90 days to Mar 30, 2026: 1 insider bought $29K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Evans DaronCFO | Buy | 10,000 | $2.85 | $29K |
| Dec 16, 2025 | Roberts Brian KennethChief Medical Officer | Buy | 28,000 | $1.70 | $48K |
| Dec 16, 2025 | Hogenhuis WladimirDirector | Buy | 5,650 | $1.69 | $10K |
| Dec 15, 2025 | Evans DaronCFO | Buy | 40,000 | $1.77 | $71K |
| Dec 15, 2025 | Elam Nevan CCEO | Buy | 32,000 | $1.59 | $51K |
| Dec 15, 2025 | Karnawat Sunil RatilalChief Commercial Officer | Buy | 12,000 | $1.62 | $19K |
| Dec 15, 2025 | Evans DaronCFO | Buy | 2,500 | $1.79 | $4K |
| Dec 15, 2025 | Karnawat Sunil RatilalChief Commercial Officer | Buy | 100 | $1.60 | $160 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance